Document is current

Article History

Received: 11 May 2020

Accepted: 20 July 2020

First Online: 31 July 2020

Compliance with ethical standards

:

: GIS: GIS has received research funding from Eli Lilly, Merck KGaA/EMD-Serono, Merck, and Sierra Oncology. He has served on advisory boards for Pfizer, Eli Lilly, G1 Therapeutics, Roche, Merck KGaA/EMD-Serono, Sierra Oncology, Bicycle Therapeutics, Fusion Pharmaceuticals, Cybrexa Therapeutics, Astex, Almac, Ipsen, Bayer, Angiex, Daiichi Sankyo, Seattle Genetics, Boehringer Ingelheim, ImmunoMet, Asana, Artios, Atrin and Concarlo Holdings. In addition, he holds a patent entitled, “Dosage regimen for sapacitabine and seliciclib,” also issued to Cyclacel Pharmaceuticals, and a pending patent, entitled, “Compositions and Methods for Predicting Response and Resistance to CDK4/6 Inhibition,” together with Liam Cornell.PL: None.DCC: Consulting/Advisory for Nektar, Pfizer, Torque, HUYA, and PureTech, relationship with self.LM: Employee of Genentech, Inc., shareholder of F. Hoffmann La Roche, Ltd.YY: Employee of Genentech, Inc., shareholder of F. Hoffmann La Roche, Ltd.MW: Employee of Genentech, Inc., shareholder of F. Hoffmann La Roche, Ltd.IC: Employee of Genentech, Inc., shareholder of F. Hoffmann La Roche, Ltd.; Employee of Celltrion, Inc., shareholder of Celltrion, Inc.PP: Employee of Genentech, Inc., shareholder of F. Hoffmann La Roche, Ltd.ITC: Employee of Genentech, Inc., shareholder of F. Hoffmann La Roche, Ltd.RDM: Employee of Genentech, Inc., shareholder of F. Hoffmann La Roche, Ltd.JCB: Research Funding - All to Institution: Gilead, Genentech/Roche, BMS, Five Prime, Lilly, Merck, MedImmune, Celgene, EMD Serono, Taiho, Macrogenics, GSK, Novartis, OncoMed, LEAP, TG Therapeutics, AstraZeneca, BI, Daiichi Sankyo, Bayer, Incyte, Apexigen, Koltan, SynDevRex, Forty Seven, AbbVie, Array, Onyx, Sanofi, Takeda, Eisai, Celldex, Agios, Cytomx, Nektar, ARMO, Boston Biomedical, Ipsen, Merrimack, Tarveda, Tyrogenex, Oncogenex, Marshall Edwards, Pieris, Mersana, Calithera, Blueprint, Evelo, FORMA, Merus, Jacobio, Effector, Novocare, Arrys, Tracon, Sierra, Innate, Arch Oncology, Prelude Oncology, Unum Therapeutics, Vyriad, Harpoon, ADC, Amgen, Pfizer, Millennium, Imclone, Acerta Pharma, Rgenix, Bellicum, Gossamer Bio, Arcus Bio, Seattle Genetics, TempestTx, Shattuck Labs. Consulting /Advisory Role - All to Institution: Gilead, Genentech/Roche, BMS, Five Prime, Lilly, Merck, MedImmune, Celgene, Taiho, Macrogenics, GSK, Novartis, OncoMed, LEAP, TG Therapeutics, AstraZeneca, BI, Daiichi Sankyo, Bayer, Incyte, Apexigen, Array, Sanofi, ARMO, Ipsen, Merrimack, Oncogenex, FORMA, Arch Oncology, Prelude Therapeutics, Phoenix Bio, Cyteir, Molecular Partners, Innate, Torque, Tizona, Janssen, Tolero, TD2 (Translational Drug Development), Amgen, Seattle Genetics, Moderna Therapeutics, Tanabe Research Laboratories, Beigene, Continuum Clinical, Agois. Food/Beverage/Travel: Gilead, Genentech/Roche, BMS, Lilly, Merck, MedImmune, Celgene, Taiho, Novartis, OncoMed, BI, ARMO, Ipsen, Oncogenex, FORMA.

: This study was conducted at 6 institutions in the United States and Australia in accordance with the 1964 Helsinki declaration and it later amendments, as well as the International Conference on Harmonization E6 Guidelines for Good Clinical Practice. The study was approved by regulatory and ethics committees at each institution and was registered at Clinicaltrials.gov, NCT01562275. Informed consent was obtained from all individual participants included in the study.